Kelman Lazarov Inc. held its position in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,460 shares of the medical research company’s stock at the end of the first quarter. Kelman Lazarov Inc.’s holdings in Amgen were worth $240,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Meritage Portfolio Management raised its position in shares of Amgen by 0.5% in the first quarter. Meritage Portfolio Management now owns 45,730 shares of the medical research company’s stock valued at $7,503,000 after buying an additional 230 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Amgen by 81.0% in the first quarter. Acadian Asset Management LLC now owns 4,770 shares of the medical research company’s stock valued at $784,000 after buying an additional 2,135 shares during the last quarter. BTR Capital Management Inc. acquired a new position in shares of Amgen during the first quarter valued at approximately $249,000. Korea Investment CORP raised its position in shares of Amgen by 48.5% in the first quarter. Korea Investment CORP now owns 744,449 shares of the medical research company’s stock valued at $122,142,000 after buying an additional 242,988 shares during the last quarter. Finally, Intermede Investment Partners Ltd raised its position in shares of Amgen by 7.8% in the first quarter. Intermede Investment Partners Ltd now owns 232,816 shares of the medical research company’s stock valued at $38,198,000 after buying an additional 16,945 shares during the last quarter. 78.86% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) opened at 162.42 on Friday. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21. The company has a market cap of $119.44 billion, a P/E ratio of 15.43 and a beta of 1.37. The company’s 50 day moving average price is $160.16 and its 200-day moving average price is $160.84.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.00 by $0.15. The firm had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. Amgen’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period last year, the company earned $2.90 EPS. On average, analysts forecast that Amgen Inc. will post $12.43 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/06/17/amgen-inc-amgn-position-held-by-kelman-lazarov-inc-updated.html.

Several brokerages have recently commented on AMGN. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $174.10 price objective for the company. in a report on Monday, March 13th. Mizuho set a $195.00 price objective on Amgen and gave the stock a “buy” rating in a report on Friday, March 10th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $189.00 price objective on shares of Amgen in a report on Tuesday, March 14th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $193.00 target price on shares of Amgen in a research note on Tuesday, March 14th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $212.00 target price on shares of Amgen in a research note on Monday, March 6th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $185.49.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.